Synairgen plc (SNG.L) LSE
0.95
+0(+0.00%)
Currency In GBp
- General
- Statistics
- Historical Data
- Profile
- Financials
Synairgen plc
Address
Mailpoint 810
Southampton, SO16 6YD
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 23 8051 2800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
36
First IPO Date
October 26, 2004
Key Executives
| Name | Title | Pay | Year Born |
| Richard Marsden | Chief Executive Officer, MD & Executive Director | 328,000 | 1967 |
| Donna Davies | Co-Founder & Member of Scientific Advisory Board | 40,000 | N/A |
| Ratko Djukanovic | Co-Founder & Member of Scientific Advisory Board | 40,000 | N/A |
| Stephen T. Holgate | Co-Founder & Member of Scientific Advisory Board | 40,000 | 1947 |
| Joseph Tregonning Colliver | Chief Financial Officer & Executive Director | 197,410 | 1980 |
| Gareth E. Walters | Chief Regulatory Officer | 0 | 1959 |
| Marcin Mankowski | Chief Medical Officer | 0 | N/A |
| Victoria Tear | Head of Laboratory | 0 | N/A |
| Richard Francis | Senior Vice President and Head of CMC & Quality | 0 | N/A |
| Simon William Holden | Company Secretary | 0 | 1976 |
| Jody Brookes | Senior Vice President & Head of Clinical Operations | 0 | N/A |
Description
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
